Warfarin Potassium

PONTE VEDRA, Fla.--( BUSINESS WIRE )-- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), announced today its engagement in three key events leading up to and during the 43 rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025 in San Francisco, California. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. Quang X. Pham , Chairman and Chief Executive Officer of Cadrenal Therapeutics, will join top biopharmaceutical leaders for two-days of discussion on January 11 – 12, 2025 hosted by Longwood Healthcare Leaders . The meeting gathers leaders from government, pharma, biotech, academia, and investment communities to address critical challenges facing the life sciences ecosystem today. Additionally, Mr. Pham is honored to join leading healthcare executives at the prestigious Nasdaq Opening Bell Ceremony on Monday, January 13, 2025, in conjunction with the first day of the 43rd Annual J.P. Morgan Healthcare Conference. Taking place from 5:30 AM to 7:30 AM PT at the Nasdaq Entrepreneurial Center in San Francisco, the event will set the stage for a dynamic week of activities that will shape the healthcare and life sciences sector in 2025. Mr. Pham and Chief Operating Officer, Jeff Cole , will join one-on-one investor and partnering meetings during the 43 rd J.P. Morgan Healthcare Conference Week to provide updates on the development of tecarfarin and its potential to be a more effective anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. This update will outline the company's roadmap for finalization of the clinical development plan for regulatory approval and pre-commercial activities for tecarfarin and key business and strategic priorities for 2025. To schedule a meeting with management, please contact Patrick Mikus at LaVoieHealthScience at (617) 351-0244 or pmikus@lavoieheatlhscience.com . “We look forward to take part in these key events around the 43 rd Annual J.P. Morgan Healthcare Conference Week, as they provide an invaluable platform to share our 2025 Phase 3 clinical development and regulatory execution plan for tecarfarin and our three-year vision for Cadrenal,” said Mr. Pham. About Cadrenal Therapeutics Cadrenal Therapeutics, Inc. is a biopharmaceutical company in advanced clinical development focused on tecarfarin, a novel oral and reversible anticoagulant for the prevention of heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions. Tecarfarin is a vitamin K antagonist (VKA) representing the first new innovation in 70 years in VKA anticoagulation. Tecarfarin is designed to be a superior and safer chronic anticoagulant oral therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. Cadrenal Therapeutics’ Phase 3-ready drug candidate, tecarfarin, is supported by extensive data demonstrating its potential as an alternative to warfarin, resulting in fewer adverse events such as strokes, heart attacks, bleeds, and deaths. Tecarfarin received an orphan drug designation for heart failure patients with implanted left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease (ESKD) patients with atrial fibrillation. The company also plans to investigate tecarfarin in patients with mechanical heart valves who face anticoagulation challenges due to genetic warfarin resistance, polypharmacy, or kidney impairment. For more information, please visit www.cadrenal.com and connect with the company on LinkedIn . Safe Harbor Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding tecarfarin’s potential to be a more effective anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to be a more effective anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Biotech startup Enveda has raised a $130 million Series C, the Colorado company said Thursday morning. Founded and led by early Recursion employee Viswa Colluru, the startup will use the funds to back its pipeline of 10 drug development candidates, including one that entered human studies last month. The new financing will get the 250-employee startup to clinical proof-of-concept for three to five of those candidates, Colluru said in a phone interview on Thursday. That includes a once-daily, oral obesity drug that will enter human trials around the middle of next year, he said. The five-year-old company maps the chemistry of plants and employs machine learning and other methods to create therapeutics based on those insights. Enveda believes nature can serve as the foundation for a new generation of medicines, just as morphine, aspirin, metformin, warfarin and others have all come from nature. “It’s funny, when you think about the core of Enveda being natural products, every pharma company would scoff at that and be like, ‘Look, we tried that. It’s not an interesting place,’” Shaquille Vayda, principal at Lux Capital, told Endpoints News last year. Enveda entered the clinic last month with its first drug candidate, ENV-294, an experimental oral treatment for atopic dermatitis, among other inflammatory indications. The drug has attracted pharma interest, Colluru said, noting the company could explore partnerships on some of its programs. It had expected to enter human trials in 2023, Colluru told Endpoints at the time of a December 2022 Series B announcement. Beyond anti-inflammatories, Enveda is also working in obesity (with a hormone mimetic), multiple forms of fibrosis, chronic pain and neurological indications. It’s working on MRGPRX4 antagonists, NLRP3 and TL1A pathway inhibitors, and TGR5 agonists, among others. With the new funds, Enveda has now raised a total of $360 million from Lux Capital, Dimension Capital , Microsoft, Kinnevik, Baillie Gifford and multiple other investors. And it has grown quickly: Colluru previously told Endpoints he initially invested $50,000 of his own money into the company alongside $220,000 from friends and family. He said the company now has flexibility with regard to its next financing step. “The potential here is massive, but there’s enough wood to chop just on the therapeutics side, where I think there’s a $50 billion company to be built just on therapeutics alone in the next decade,” Zavain Dar, a co-founder of VC firm Dimension, previously told Endpoints. The company also has a footprint in India, where Colluru grew up.